News
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.
1d
Stocktwits on MSNGSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail OptimismU.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...
Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...
Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...
Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
This Original Lifetime Movie, "Pretty Hurts," airs June 28, at 8 p.m.
Shares of GSK PLC GSK rose 1.74% to £15.50 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.23% to 8,884.92. GSK PLC ...
GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results